IL160077A0 - Processes for preparing calcium salt forms of statins - Google Patents

Processes for preparing calcium salt forms of statins

Info

Publication number
IL160077A0
IL160077A0 IL16007702A IL16007702A IL160077A0 IL 160077 A0 IL160077 A0 IL 160077A0 IL 16007702 A IL16007702 A IL 16007702A IL 16007702 A IL16007702 A IL 16007702A IL 160077 A0 IL160077 A0 IL 160077A0
Authority
IL
Israel
Prior art keywords
statins
processes
calcium salt
salt forms
preparing calcium
Prior art date
Application number
IL16007702A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/037,412 external-priority patent/US6528661B2/en
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL160077A0 publication Critical patent/IL160077A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
IL16007702A 2001-08-16 2002-08-16 Processes for preparing calcium salt forms of statins IL160077A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31281201P 2001-08-16 2001-08-16
US10/037,412 US6528661B2 (en) 2000-11-16 2001-10-24 Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
PCT/US2002/026012 WO2003016317A1 (fr) 2001-08-16 2002-08-16 Procedes permettant de preparer des formes salines calciques de statines

Publications (1)

Publication Number Publication Date
IL160077A0 true IL160077A0 (en) 2004-06-20

Family

ID=26714105

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16007702A IL160077A0 (en) 2001-08-16 2002-08-16 Processes for preparing calcium salt forms of statins
IL160077A IL160077A (en) 2001-08-16 2004-01-27 Processes for preparing calcium salt forms of statins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160077A IL160077A (en) 2001-08-16 2004-01-27 Processes for preparing calcium salt forms of statins

Country Status (17)

Country Link
EP (1) EP1425287A4 (fr)
JP (2) JP4188826B2 (fr)
CN (1) CN100430405C (fr)
AU (1) AU2002324715B2 (fr)
CA (1) CA2450820C (fr)
CZ (1) CZ2004337A3 (fr)
HR (1) HRPK20040255B3 (fr)
HU (1) HUP0500616A3 (fr)
IL (2) IL160077A0 (fr)
IS (1) IS7148A (fr)
MX (1) MXPA04001451A (fr)
NO (1) NO20041082L (fr)
NZ (1) NZ529913A (fr)
PL (1) PL370407A1 (fr)
SK (1) SK1402004A3 (fr)
TR (1) TR200302281T2 (fr)
WO (1) WO2003016317A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
NZ526022A (en) * 2000-11-16 2005-04-29 Teva Pharma Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (fr) 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
CA2412012C (fr) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Matrice extracellulaire resorbable contenant du collagene i et du collagene ii pour la reconstruction de cartilage
BR0215644A (pt) 2002-03-18 2004-12-21 Biocon Ltd Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado
EP1585736A2 (fr) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Procede de preparation de rosuvastatine
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CA2513837A1 (fr) * 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Formes cristallines de calcium de pitavastatine
SI1631533T1 (sl) 2003-04-22 2009-08-31 Bicon Ltd Nov postopek za stereoselektivno redukcijo beta - ketoestrov
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
BRPI0412786A (pt) * 2003-07-25 2006-09-26 Avecia Pharmaceuticals Ltd processo para a preparação de um composto, e, composto
AU2003269477A1 (en) * 2003-08-26 2005-03-10 Biocon Limited Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt
EP1816126A1 (fr) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Procédé pour la préparation de rosuvastatine calcique
WO2005023778A2 (fr) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Procede de preparation de sels calciques de rosuvastatine
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
WO2005026107A1 (fr) 2003-09-18 2005-03-24 Biocon Limited Nouveau processus de preparation de tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
EP1678148A1 (fr) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Procede de preparation de rosuvastatine calcique amorphe
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
CA2546894C (fr) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Norme de reference pour la caracterisation de la rosuvastatine
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1711489B1 (fr) * 2003-12-29 2012-12-26 LEK Pharmaceuticals d.d. Procede pour preparer un compose amorphe d'acide (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetique
CZ200486A3 (cs) * 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (fr) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Sels de magnesium amorphes de la rosuvastatine
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
BRPI0514189A (pt) * 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
JP2008515931A (ja) 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
CN100371709C (zh) * 2005-12-12 2008-02-27 重庆医药工业研究院有限责任公司 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法
WO2007125547A2 (fr) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Nouveau procédé faisant intervenir des statines et leurs sels acceptables sur le plan pharmaceutique
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (fr) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Procédé pour la préparation d'ester méthylique de rosuvastatine
WO2010089770A2 (fr) 2009-01-19 2010-08-12 Msn Laboratories Limited Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables
EP2526099B1 (fr) 2010-01-18 2016-03-30 MSN Laboratories Limited Procédé amélioré pour la préparation d'intermédiaires amides et leur utilisation
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
EP3178812A1 (fr) * 2010-11-12 2017-06-14 Hetero Research Foundation Nouveaux polymorphes de calcium de pitavastatine
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102875504A (zh) * 2011-07-13 2013-01-16 华南理工大学 4,5,6,7-四氢普伐他汀及其盐在心血管上的用途
CN102302452B (zh) * 2011-09-14 2012-11-21 海南美大制药有限公司 匹伐他汀钙脂质体固体制剂
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
CN106029895B (zh) * 2014-02-06 2021-07-16 株式会社Api 瑞舒伐他汀钙及其中间体的生产方法
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN105111173B (zh) * 2015-06-26 2017-06-23 上海应用技术学院 他汀含氟衍生物及其用途
CN105017231B (zh) * 2015-06-26 2018-01-26 上海应用技术学院 多取代吲哚类他汀含氟修饰物及其用途
CN113620871A (zh) 2015-08-05 2021-11-09 株式会社Api 生产匹伐他汀钙的方法
CN111362856B (zh) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 一种利用微反应装置生产阿托伐他汀钙的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5817443B2 (ja) * 1976-11-02 1983-04-07 三共株式会社 Ｍｌ−２３６ｂ金属塩を主成分とする高脂血症治療剤
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
US5669156A (en) * 1996-08-28 1997-09-23 Fleetwood Systems, Inc. Can end curing system with magnetic fanning and belt conveying
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
EP1161236A1 (fr) * 1999-03-08 2001-12-12 Merck & Co., Inc. Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
NZ526022A (en) * 2000-11-16 2005-04-29 Teva Pharma Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2007205725A1 (en) * 2000-11-30 2007-08-30 Teva Pharmaceutical Industries Ltd. Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL365312A1 (en) * 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
CA2456095C (fr) * 2001-08-31 2010-05-11 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)

Also Published As

Publication number Publication date
HRP20040255A2 (en) 2004-08-31
SK1402004A3 (sk) 2005-01-03
JP4188826B2 (ja) 2008-12-03
IL160077A (en) 2007-10-31
PL370407A1 (en) 2005-05-30
IS7148A (is) 2004-02-11
TR200302281T2 (tr) 2004-09-21
WO2003016317A1 (fr) 2003-02-27
CN1543468A (zh) 2004-11-03
EP1425287A1 (fr) 2004-06-09
CA2450820A1 (fr) 2003-02-27
CN100430405C (zh) 2008-11-05
AU2002324715B2 (en) 2009-03-12
HRPK20040255B3 (en) 2006-02-28
HUP0500616A2 (hu) 2005-11-28
MXPA04001451A (es) 2005-02-17
NZ529913A (en) 2005-03-24
JP2009024008A (ja) 2009-02-05
HUP0500616A3 (en) 2011-07-28
NO20041082L (no) 2004-03-15
JP2005500382A (ja) 2005-01-06
CZ2004337A3 (cs) 2005-01-12
CA2450820C (fr) 2011-03-15
EP1425287A4 (fr) 2005-09-07

Similar Documents

Publication Publication Date Title
HUP0500616A3 (en) Processes for preparing calcium salt forms of statins
HK1082735A1 (en) Process for preparing the calcium salt of rosuvastatin
IL173858A0 (en) Process for preparation of rosuvastatin calcium
IL156949A0 (en) Method of synthesizing camptothecin-relating compounds
HK1087405A1 (en) Improved production of the rosuvastatin calcium salt
SI1390023T1 (sl) Farmacevtske soli spojin 1-fenil-3-dimetilamino-propana
AP2002002550A0 (en) Chiral salt resolution
NZ523557A (en) Calcium salt of valsartan
ZA200409981B (en) Novel formate salt of O-desmethyl-venlafaxine
IL159626A0 (en) Crystalline forms of atorvastatin calcium and processes for the preparation thereof
PL367278A1 (en) Method for inhibiting calcium salt scale
EP1572638A4 (fr) Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
PL367302A1 (en) Method for inhibiting calcium salt scale
IL143106A (en) Process for the preparation of diphenylmethylthioacetamide
PL355958A1 (en) Application of statins for inhibiting formation of osteoclasts
HUP0500644A3 (en) Method of synthesizing phenol-containing compounds
IL159355A0 (en) Process for the preparation of nitrile compounds
IL161386A0 (en) Bone anti-resorptive compounds
SG108831A1 (en) Process for preventing formation of scale
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
HUP0303123A3 (en) Method of purifying pravastatin or its pharmacologically acceptable salt
PL368905A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
AU2002329110A1 (en) Method for preparing calcium gluconate
SI1395580T1 (en) Method for the purification of triazolylmethylepoxides
HU0100184V0 (en) Method for forming of smokingset

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed